Lipella Pharmaceuticals Inc. (NASDAQ:LIPO – Get Free Report) shares fell 29.1% during trading on Wednesday . The company traded as low as $0.21 and last traded at $0.21. 47,270 shares were traded during mid-day trading, a decline of 92% from the average session volume of 594,642 shares. The stock had previously closed at $0.2961.
Lipella Pharmaceuticals Trading Down 29.1%
The firm’s 50 day moving average price is $0.42 and its two-hundred day moving average price is $0.80. The company has a market capitalization of $970,410.00, a price-to-earnings ratio of -0.05 and a beta of -0.02.
About Lipella Pharmaceuticals
Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).
See Also
- Five stocks we like better than Lipella Pharmaceuticals
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- What to Know About Investing in Penny Stocks
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
- What is the Shanghai Stock Exchange Composite Index?
- Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish
Receive News & Ratings for Lipella Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipella Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
